Halogenated cytisine derivatives as agonists at human neuronal nicotinic acetylcholine receptor subtypes.
Cytisine (cy) is a potent and competitive partial agonist at alpha4 subunit-containing nicotinic acetylcholine (nACh) receptors while at homomeric alpha7-nACh receptors it behaves as a full agonist with a relatively lower potency. In the present study, we assessed the effects of bromination or iodination of the pyridone ring of cy and N-methylcytisine (N-Me-cy) on the effects of these compounds on recombinant human (h) alpha7, halpha4beta2 and halpha4beta4 nACh receptors expressed in clonal cell lines and Xenopus oocytes. Halogenation at C(3) of cy or N-Me-cy usually brings about a marked increase in both affinity and efficacy at halpha7, halpha4beta2 and halpha4beta4 nACh, the extent of which depends on whether the halogen is bromine or iodine, and upon receptor subtype. The effects of halogenation at C(5) are strongly influenced by the specific halogen substituent so that bromination causes a decrease in both affinity and efficacy while iodination decreases affinity but its effects on efficacy range from a decrease (halpha7, halpha4beta4 nACh receptors) to a marked increase (halpha4beta2 nACh receptors). Based on these findings, which differ from those showing that neither the affinity nor efficacy of nicotine, 3-(2-azetidinylmethoxy)-pyridine or epibatidine are greatly affected by halogenation, dehalogenation or halogen exchange at equivalent positions, we suggest that cy, N-Me-cy and their halo-isosteres bind to neuronal nACh receptors in a different orientation allowing the halogen atom to interact with a hydrophobic halogen-accepting region within the predominantly hydrophobic agonist-binding pocket of the receptors.
Slater
Y E
YE
School of Biological and Molecular Sciences, Oxford Brookes University, Gipsy Lane Campus, Oxford OX3 0BP, UK.
Houlihan
L M
LM
Maskell
P D
PD
Exley
R
R
Bermúdez
I
I
Lukas
R J
RJ
Valdivia
A C
AC
Cassels
B K
BK
D000470:Alkaloids / Q000737:chemistry / Q000494:pharmacology*; D000818:Animals; D001392:Azocines; D001966:Bromine / Q000737:chemistry; D002460:Cell Line; D006801:Humans; D007455:Iodine / Q000737:chemistry; D018722:Nicotinic Agonists / Q000737:chemistry / Q000494:pharmacology*; D018408:Patch-Clamp Techniques; D011807:Quinolizines; D011869:Radioligand Assay; D011978:Receptors, Nicotinic / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology; D011994:Recombinant Proteins / Q000378:metabolism; D013329:Structure-Activity Relationship; D014982:Xenopus laevis; D000093843:Quinolizidine Alkaloids
D000470:Alkaloids; D001392:Azocines; D001966:Bromine; D007455:Iodine; D018722:Nicotinic Agonists; D011807:Quinolizines; D011978:Receptors, Nicotinic; D011994:Recombinant Proteins; C427403:alpha(4)beta(4) nicotinic receptor; C403531:nicotinic receptor alpha4beta2; C004712:cytisine; D000093843:Quinolizidine Alkaloids; C034245:N-methylcytisine